To prevent the postoperative paralysis associated with the lower limb, a self-expandable metallic stent(SEMS)was placed, and systemic chemotherapy had been Polyclonal hyperimmune globulin administered consequently. After 4 classes of SOX, Hartmann’s procedure had been carried out. The patient failed to develop lower limb paralysis and is alive without recurrence two years and a few months postoperatively. This instance suggests that preoperative metallic SEMS positioning and neoadjuvant chemotherapy could be a highly effective treatment for locally higher level cancer of the colon with obstruction and intrusion associated with the adjacent areas.We report a case of unresectable higher level esophagogastric junction carcinoma that has been addressed with nab-paclitaxel and ramucirumab, which resulted in full reaction and salvage surgery. A 57-year-old male complained of upper stomach vexation. While going to a hospital for diabetes mellitus, upper gastrointestinal endoscopy was done. A tumor protruding from the gastric cardia into the abdominal esophagus had been found, and histological evaluation revealed well-differentiated adenocarcinoma. Several liver metastases and para-aortic lymph node metastases had been found on abdominal contrast-enhanced CT. The patient had been identified as having stage Ⅳ cancer, and chemotherapy was performed as unresectable advanced esophagogastric junction carcinoma. S-1 plus CDDP therapy was begun once the first-line treatment. After 2 programs of S-1 plus CDDP therapy, tumefaction markers were elevated. More, the disease had been judged is highly toxic and refractory to treatment; therefore, we began nab-paclitaxel and ramucirumab while the secondary Electrical bioimpedance treatment. After 4 classes, normalization of tumor markers, disappearance of liver metastases, and marked reduction of increased lymph nodes were seen. However, PET-CT showed increased uptake, in keeping with the main lesion. Residual cancer could not be ruled-out; consequently, complete gastrectomy ended up being done. Histopathological study of the surgically resected specimen showed no residual tumors.A 70-year-old man had withstood thoracoscopic esophagectomy after neoadjuvant chemotherapy for thoracic esophageal squamous cell carcinoma 36 months before presentation. He was undergoing whole-brain irradiation following surgery for a solitary brain metastatic tumefaction. The main complaint was left knee discomfort during irradiation. FDG-PET/CT and MRI disclosed metastases in bilateral cauda equina S1 nerve roots. Cerebrospinal liquid evaluation also disclosed cancerous cells. He obtained chemotherapy with 2 programs of 5-fluorouracil and cisplatin after 30 Gy of spinal irradiation. To regulate neurologic symptoms, 4 courses of intrathecal chemotherapy with methotrexate, cytarabine, and betamethasone had been performed. Nevertheless, he slowly weakened and passed away 8 months after brain metastasis and 7 months after leptomeningeal carcinomatosis. The multidisciplinary therapy using irradiation and systemic and intrathecal chemotherapies could improve the survival of patients with leptomeningeal carcinomatosis of esophageal squamous cell carcinoma.Febrile neutropenia(FN)is a bad event related to chemotherapy. Because well-maintained dose power gets better pentamethylenetetrazol success rate, suppression of FN is very important. Although the incidence of FN is seen to be higher with docetaxel/cyclophosphamide(TC)therapy, it really is usually considered lower with doxorubicin/cyclophosphamide(AC)therapy, and major prophylaxis with granulocyte-colony stimulating factor(G-CSF)is not recommended. FN with AC treatments are commonly experienced in our day-to-day practice. Thus, we retrospectively compared the occurrence of FN with AC and TC therapies. We examined the info of 48 clients with primary breast cancer, consisting of 26 patients treated with AC and 22 customers with TC as perioperative chemotherapy-from January 2014 to September 2018-to determine the occurrence of FN. FN ended up being seen in 7/26 clients who received AC(26.9%)and 5/22 patients who received TC(22.7%). Excluding clients with major prophylaxis with G-CSF, FN was observed in 7/23 patients(30.4%)who obtained AC and 5/18 (27.8%)who gotten TC. The incidence of FN with AC treatment was higher than that with TC therapy in this study. Consequently, good use of G-CSF is necessary for safety also to adequately maintain dose strength for AC therapy.There is no understood advised chemotherapy after radical surgery for gastric cancer for customers that have non-curative condition. We defined good peritoneal cytology(CY1), resection margin involvement, pathological peritoneal metastasis (pP1)and pN3b as clinical non-curative facets and administered adjuvant chemotherapy with S-1 and docetaxel(DOC) (80 mg/m2 day 1-14 of S-1 for 2 days with 40 mg/m2 of DOC on day 1, every 3 days). This regime lasted for 1 year; however, if chemotherapy could be proceeded after this duration, we utilized S-1 only. We reported the outcome of 11 instances who received this treatment. There have been 6 complete gastrectomies and 5 distal gastrectomies. Clinical non-curative facets were 5 pP1, 5 pN3b, 3 CY1 and 1 resection margin involvement. At the conclusion of adjuvant therapy there have been 6 completions, 4 recurrences, and 1 patient with side effects. The primary negative event of Grade 3 or higher was neutropenia (46%). The recurrence price ended up being 63.6%. Types of relapse included 6 disseminations and 1 patient with lymph node involvement. One-, 3-, and 5-year success rates had been 100%, 72.7% and 72.7%, respectively, while the RFS ended up being 64.0 months.S-1 and DOC adjuvant chemotherapy produced accomplishment and could act as a treatment of preference for customers with advanced gastric cancer tumors with non-curative elements after a comparatively curative resection.Definitive chemoradiotherapy(CRT)for esophageal cancer may be the standard treatment and substitute for surgery. Nevertheless, the tolerability of CRT in senior customers is certainly not well known. In this research, we retrospectively analyzed 60 clients with esophageal cancer tumors have been treated with CRT(5-FU 700 mg/m2, cisplatin 70 mg/m2, radiation 60 Gy)at our medical center between January 2015 and September 2017. The patients had been divided in to 2 groups an elderly group comprising 16 patients aged >75 many years and a non-elderly group comprising 44 clients aged less then 74 years.